Pharma Sector Seeks Seamless EU Medical Device Rules
The EU Commissioner for Health & Family Welfare, Oliver Varhelyi, went on to confirm on March 20 that the regulations when it comes to...
AI in Drug Commercialization Market to Grow CAGR 24% by 2032
Global Artificial Intelligence in Drug Commercialization Market to Observe Stupendous Growth at a CAGR of 24% by 2032
The global artificial intelligence (AI) market in...
CDMO Growth and Biotechnology Outsourcing Trends
Since many contract manufacturing companies (CMOs) are the only ones able to produce the vast quantities of medications and treatments required, outsourcing has grown...
Generative AI in Pharma: Opportunities & Challenges
Regarding the readiness of the life sciences sector to successfully use generative AI in terms of infrastructure, regulatory considerations, and expertise, 67% of pharmaceutical...
Women Leaders in Biopharma: The Way Forward
According to the World Health Organization (WHO), women account for 70% of the global healthcare workforce1, significantly higher than in other industries such as...
Scalability and therapeutic potential of induced pluripotent reprogramming and neural induction using small molecules
Although we may disagree about the precise costs of bringing novel therapies to market, and even what factors contribute to those costs, it is...
Laboratory Information Management System – The 2024 Path
It is well to be noted that the Laboratory Information Management System- LIMS spectrum in 2024 happens to be a dynamic one, pushed by...
Subscribe Our Newsletter
White Papers
The Future of Digital Health
The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....
Five Best Practices to Deliver Exceptional Multichannel Experiences
A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...
The Impact and Use of Social Media in Pharmacovigilance
Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...